Genentech has announced that a phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived
Ranbaxy has entered into a strategic in-licensing agreement for the Indian market, with Medy-Tox, South Korea’s Botulinum -Toxin specialised Biotech Venture, for its cosmetic product, Neuronox. The introduction
GlaxoSmithKline (GSK) and XenoPort have reported top-line results from a phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with
Merial has licensed the Clean Genome E coli developed by Scarab Genomics for commercial production of an upcoming veterinary vaccine. Reportedly, Clean Genome E coli are K-12 strains,
Regulus Therapeutics (Regulus), Alnylam and Isis Pharmaceuticals (Isis) have reported that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a
“As we reposition the Company to unlock the value of MDS businesses, we have prepared for a smooth CEO transition as part of our succession planning process,” said
The FDA has Novartis’ approved Valturna (aliskiren and valsartan) tablets, a medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone
GENova Biotherapeutics (GENova) has signed a LOI for a strategic partnership agreement with the Hospital Medical Information Department of Suncheon Cheongam University in Seoul, South Korea to gain
Rexahn Pharmaceuticals (Rexahn) has reached an agreement to close on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical (Teva) for the development of its novel
Intarcia Therapeutics (Intarcia) has initiated enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.